08.06.2015 • News

Solvay Opens Biotechnology Lab in Brazil

Solvay has opened its first fully dedicated Industrial Biotechnology Laboratory (IBL) in Paulinia, Brazil.
The Belgian chemical producer said the lab is designed to boost the development of innovations and solutions based on sustainable chemistry and used in a growing range of end-markets.
The fully integrated laboratory will focus chiefly on researching new processes and molecules derived from biomass, which is mostly plant or vegetable-based and abundantly available in Brazil with its favorable climate and vast surface.
Louis Neltner, general manager of Solvay's Research & Innovation group, said the new lab will allow the company to “further nourish its innovation portfolio, using renewable resources, with tailored solutions to meet sustainability demands from customers in multiple end-markets.”
"Thanks to Brazil's wide variety of biomass, competitive agricultural businesses and biotech expertise the country has all the required conditions to develop and grow products and solutions based on renewable resources."
The lab's researchers will work jointly with the group's global business units in Solvay's research and innovation centers worldwide as well as with external partners including public and private institutions. Research programs in place include projects in flavors, fragrances, surfactants, cellulose derivatives and solvents.
Solvay has been developing products and solutions based on bio-sourced raw materials such as ethanol and glycerol for several decades with an eye toward meeting the challenges posed by the scarcity of resources amid growing industrialization, urbanization and an increasing number of consumers.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read